BACKGROUND: Loss of genomic imprinting (LOI) of the insulin-like growth factor-2 gene (IGF2) is an epigenetic change involving abnormal activation of the normally silent maternally inherited allele. LOI of IGF2 gene is found in tumor tissue, normal adjoining mucosa and peripheral blood lymphocytes (PBL) of some patients with colorectal cancer (CRC), suggesting that this alteration precedes and is a risk factor for CRC. However, whether LOI of IGF2 is transitory or remains a permanent epigenetic alteration is unknown. RESULTS: Four-hundred patients, mean age 60.7 years (range 15-95), 287 (80%) Caucasian were studied. This included 210 (51.4%) patients with no colorectal neoplasia, and 190 (48.6) with colorectal neoplasia. LOI of IGF2 was present in all age strata examined, and no statistically significant association across age strata (p trend > 0.05) was noted. Forty-nine patients had repeat analysis of blood imprinting status at a mean follow up time of 38.2 +/- 12.9 months. All but three patients had the same imprinting status at follow up (94% agreement, kappa 0.79, p < 0.001). Genomic imprinting was stable for patients with and without colorectal neoplasia. METHODS: Standard RT-PCR assays for imprinting analysis of IGF2 were performed on PBL from ApaI informative individuals recruited at baseline and repeated 1 to 3 years later. Prevalence of LOI of IGF2 was also evaluated according to age strata. CONCLUSION: LOI of the IGF2 gene in PBL appears to be a stable epigenetic phenomenon in most patients. Furthermore, LOI of IGF2 was not associated with age, suggesting an inherited or congenital epigenetic event. These findings support the concept that LOI of IGF2 may be a useful risk factor for CRC predisposition.
BACKGROUND: Loss of genomic imprinting (LOI) of the insulin-like growth factor-2 gene (IGF2) is an epigenetic change involving abnormal activation of the normally silent maternally inherited allele. LOI of IGF2 gene is found in tumor tissue, normal adjoining mucosa and peripheral blood lymphocytes (PBL) of some patients with colorectal cancer (CRC), suggesting that this alteration precedes and is a risk factor for CRC. However, whether LOI of IGF2 is transitory or remains a permanent epigenetic alteration is unknown. RESULTS: Four-hundred patients, mean age 60.7 years (range 15-95), 287 (80%) Caucasian were studied. This included 210 (51.4%) patients with no colorectal neoplasia, and 190 (48.6) with colorectal neoplasia. LOI of IGF2 was present in all age strata examined, and no statistically significant association across age strata (p trend > 0.05) was noted. Forty-nine patients had repeat analysis of blood imprinting status at a mean follow up time of 38.2 +/- 12.9 months. All but three patients had the same imprinting status at follow up (94% agreement, kappa 0.79, p < 0.001). Genomic imprinting was stable for patients with and without colorectal neoplasia. METHODS: Standard RT-PCR assays for imprinting analysis of IGF2 were performed on PBL from ApaI informative individuals recruited at baseline and repeated 1 to 3 years later. Prevalence of LOI of IGF2 was also evaluated according to age strata. CONCLUSION: LOI of the IGF2 gene in PBL appears to be a stable epigenetic phenomenon in most patients. Furthermore, LOI of IGF2 was not associated with age, suggesting an inherited or congenital epigenetic event. These findings support the concept that LOI of IGF2 may be a useful risk factor for CRC predisposition.
Authors: J D Ravenel; K W Broman; E J Perlman; E L Niemitz; T M Jayawardena; D W Bell; D A Haber; H Uejima; A P Feinberg Journal: J Natl Cancer Inst Date: 2001-11-21 Impact factor: 13.506
Authors: Marcia Cruz-Correa; Hengmi Cui; Francis M Giardiello; Neil R Powe; Linda Hylind; Angela Robinson; David F Hutcheon; David R Kafonek; Sheri Brandenburg; Yiqian Wu; Xiaobing He; Andrew P Feinberg Journal: Gastroenterology Date: 2004-04 Impact factor: 22.682
Authors: G J Pommier; F L Garrouste; F el Atiq; M Roccabianca; J L Marvaldi; M M Remacle-Bonnet Journal: Cancer Res Date: 1992-06-01 Impact factor: 12.701
Authors: Karen Woodson; Andrew Flood; Lisa Green; Joseph A Tangrea; Jeffrey Hanson; Brooks Cash; Arthur Schatzkin; Phillip Schoenfeld Journal: J Natl Cancer Inst Date: 2004-03-03 Impact factor: 13.506
Authors: Cathrine Hoyo; Amy P Murtha; Joellen M Schildkraut; Randy L Jirtle; Wendy Demark-Wahnefried; Michele R Forman; Edwin S Iversen; Joanne Kurtzberg; Francine Overcash; Zhiqing Huang; Susan K Murphy Journal: Epigenetics Date: 2011-07-01 Impact factor: 4.528
Authors: Ellen Perkins; Susan K Murphy; Amy P Murtha; Joellen Schildkraut; Randy L Jirtle; Wendy Demark-Wahnefried; Michele R Forman; Joanne Kurtzberg; Francine Overcash; Zhiqing Huang; Cathrine Hoyo Journal: J Pediatr Date: 2012-02-17 Impact factor: 4.406
Authors: Rae-Chi Huang; John C Galati; Sally Burrows; Lawrence J Beilin; Xin Li; Craig E Pennell; Jam van Eekelen; Trevor A Mori; Leon A Adams; Jeffrey M Craig Journal: Clin Epigenetics Date: 2012-11-13 Impact factor: 6.551
Authors: Cathrine Hoyo; Kimberly Fortner; Amy P Murtha; Joellen M Schildkraut; Adelheid Soubry; Wendy Demark-Wahnefried; Randy L Jirtle; Joanne Kurtzberg; Michele R Forman; Francine Overcash; Zhiqing Huang; Susan K Murphy Journal: Cancer Causes Control Date: 2012-03-06 Impact factor: 2.506
Authors: A Soubry; S K Murphy; F Wang; Z Huang; A C Vidal; B F Fuemmeler; J Kurtzberg; A Murtha; R L Jirtle; J M Schildkraut; C Hoyo Journal: Int J Obes (Lond) Date: 2013-10-25 Impact factor: 5.095
Authors: Yue Li; Changchun Xie; Susan K Murphy; David Skaar; Monica Nye; Adriana C Vidal; Kim M Cecil; Kim N Dietrich; Alvaro Puga; Randy L Jirtle; Cathrine Hoyo Journal: Environ Health Perspect Date: 2015-06-26 Impact factor: 9.031
Authors: Djeda Belharazem; Matthias Kirchner; Franziska Geissler; Peter Bugert; Martin Spahn; Burkhard Kneitz; Hubertus Riedmiller; Christian Sauer; Stefan Küffer; Lutz Trojan; Christian Bolenz; Maurice Stephan Michel; Alexander Marx; Philipp Ströbel Journal: Endocr Connect Date: 2012-10-24 Impact factor: 3.335
Authors: Carmen Naturil-Alfonso; María Dels Desamparats Saenz-de-Juano; David S Peñaranda; José S Vicente; Francisco Marco-Jiménez Journal: PLoS One Date: 2012-12-12 Impact factor: 3.240